1-3 of 3
Huan J. Zhu, MD, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Results of a Phase 2 Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, In Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis

Rami S. Komrokji, MD, Martha Wadleigh, MD, John F. Seymour, MD, PhD, Andrew W. Roberts, MD, PhD, Luen Bik To, Huan J. Zhu, MD, PhD, Ruben A. Mesa, MD
Journal: Blood
Blood (2011) 118 (21): 282.
https://doi.org/10.1182/blood.V118.21.282.282
Published: 2011
Journal Articles

Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia/ Polycythemia Vera Myelofibrosis.

Srdan Verstovsek, MD, PhD, Olatoyosi Odenike, MD, Bart Scott, MD, Zeev Estrov, MD, Jorge Cortes, MD, Deborah A. Thomas, MD, Jeanette Wood, PhD, Kantharaj Ethirajulu, PhD, Ann Lowe, MD, Huan J. Zhu, MD, PhD, Hagop Kantarjian, MD, H. Joachim Deeg, MD
Journal: Blood
Blood (2009) 114 (22): 3905.
https://doi.org/10.1182/blood.V114.22.3905.3905
Published: 2009
Journal Articles

Phase-I Study of the Novel Oral JAK-2 Inhibitor SB1518 in Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity.

Anas Younes, MD, Michelle Fanale, M.D., Peter McLaughlin, Amanda R Copeland, MS, Silvana de Castro Faria, Jeanette Wood, PhD, Kantharaj Ethirajulu, PhD, Huan J. Zhu, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 588.
https://doi.org/10.1182/blood.V114.22.588.588
Published: 2009